Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04877704
Status:
UNKNOWN
Last Update Posted:
2021-05-07
First Post:
2021-05-05
Brief Title:
Symprove Probiotic as an add-on to COVID-19 Management
Sponsor:
Kings College Hospital NHS Trust
Organization:
Kings College Hospital NHS Trust
Study Overview
Official Title:
The Effect of Symprove a Multi-strain Probiotic as an Adjuvant in the Management of COVID-19 in Hospitalized Patients
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The major impact of COVID-19 has been that the severity of respiratory symptoms require intensive hospital treatment There is significant mortality and many of the survivors have a delayed recovery requiring intensive prolonged rehabilitation
COVID-19 is a multi-systemic disease in which different mechanisms within the body are affected including the Gut microbiome Gut microbiome refers to the bacteria living in intestines While some bacteria is harmful many are extremely beneficial and necessary for a healthy body Many patients have gastrointestinal symptoms and there is a major change in the gut micro flora microbiome which may have an adverse effect on the respiratory symptoms The probiotic Sivomix was given to hospitalized COVID-19 patients was associated with a more rapid recovery in gastrointestinal symptoms on day 3 and 7 and an eight fold reduction in the requirement for mechanical ventilation in an open trial
This is a randomized clinical trial with a recruitment target of 60 patients admitted with COVID-19 symptoms to the general medical wards Patients will be randomized to receive the probiotic Symprove or placebo in addition to their standard of care treatment Patients will need take either probioticplacebo daily for 3 months All follow-up will be whilst they are an inpatient or as a telephone follow-up they will not need to attend at the hospital to participate
There is a biological sub-study incorporated into the protocol but participation is optional If patients consent to this they will also need to provide blood faecal and saliva samples at baseline Day 7 and final visit 3 months after randomisation Patients who consent to providing biological samples will need to visit the hospital at Day 7 and final visit
COVID-19 is a multi-systemic disease in which different mechanisms within the body are affected including the Gut microbiome Gut microbiome refers to the bacteria living in intestines While some bacteria is harmful many are extremely beneficial and necessary for a healthy body Many patients have gastrointestinal symptoms and there is a major change in the gut micro flora microbiome which may have an adverse effect on the respiratory symptoms The probiotic Sivomix was given to hospitalized COVID-19 patients was associated with a more rapid recovery in gastrointestinal symptoms on day 3 and 7 and an eight fold reduction in the requirement for mechanical ventilation in an open trial
This is a randomized clinical trial with a recruitment target of 60 patients admitted with COVID-19 symptoms to the general medical wards Patients will be randomized to receive the probiotic Symprove or placebo in addition to their standard of care treatment Patients will need take either probioticplacebo daily for 3 months All follow-up will be whilst they are an inpatient or as a telephone follow-up they will not need to attend at the hospital to participate
There is a biological sub-study incorporated into the protocol but participation is optional If patients consent to this they will also need to provide blood faecal and saliva samples at baseline Day 7 and final visit 3 months after randomisation Patients who consent to providing biological samples will need to visit the hospital at Day 7 and final visit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None